Nektar(US:NKTR) TMX Newsfile·2026-03-27 13:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Nektar to contact them to discuss legal options [1]. - A federal securities class action has been filed against Nektar, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Allegations Against Nektar - The complaint alleges that Nektar and its executives made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [5]. - Nektar's press release on December 16, 2025, revealed that the Phase 2b REZOLVE-AA trial failed to reach statistical significance due to the inclusion of ineligible patients [6]. - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [7].